📊 KALV Key Takeaways
Is KalVista Pharmaceuticals, Inc. (KALV) a Good Investment?
KalVista demonstrates strong revenue growth (+294% YoY) and maintains exceptional liquidity ($243.5M cash, 7.22x current ratio) with low debt (0.31x leverage), providing a ~2 year cash runway. However, severe operating losses (-$154.7M) with negative free cash flow (-$128.8M) and critically thin equity ($17M) against massive asset base ($339.9M) create substantial execution risk until the company achieves profitability.
KalVista shows strong liquidity with substantial cash and minimal debt, providing ~2 years of runway against heavy operating burn. However, profitability is deeply negative and equity is thin relative to liabilities, while recent revenue growth is from a small base and insufficient to offset expenses. Hold pending clearer visibility on sustainable revenue ramp and material reduction in cash burn.
KalVista Pharmaceuticals, Inc. Key Strengths (KALV)
- Exceptional revenue growth of 294% year-over-year demonstrates strong market traction
- Fortress balance sheet with $243.5M cash (71% of total assets) and low debt burden (0.31x debt-to-equity)
- Superior liquidity ratios (7.22x current, 7.21x quick) provide substantial operational flexibility and 2-year burn runway
- Robust cash position and high current/quick ratios
- Low leverage and limited long-term debt
- Strong YoY revenue growth from a low base
KALV Stock Risks: KalVista Pharmaceuticals, Inc. Investment Risks
- Severe cash burn of $127M operating cash flow and -$128.8M free cash flow with only $13.7M revenue limits runway without major inflection
- Critically undercapitalized with only $17M stockholders equity against $339.9M liabilities creates vulnerability to adverse events
- Pharmaceutical pre-profitability model carries execution risk; company must demonstrate path to gross margin sustainability and operating leverage
- Severe operating and net losses driving high cash burn
- Thin shareholders’ equity versus sizable liabilities, elevating dilution risk
- Revenue remains small and potentially volatile relative to expense base
Key Metrics to Watch
- Revenue growth trajectory and gross margin emergence
- Monthly cash burn rate trend relative to revenue acceleration
- Operating cash flow inflection point toward positive territory
- Quarterly operating cash burn vs. cash balance (runway)
- Revenue trajectory and mix (product vs. collaboration)
KalVista Pharmaceuticals, Inc. (KALV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.22x current ratio provides a solid financial cushion.
KALV Profit Margin, ROE & Profitability Analysis
KALV vs Healthcare Sector: How KalVista Pharmaceuticals, Inc. Compares
How KalVista Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KalVista Pharmaceuticals, Inc. Stock Overvalued? KALV Valuation Analysis 2026
Based on fundamental analysis, KalVista Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KalVista Pharmaceuticals, Inc. Balance Sheet: KALV Debt, Cash & Liquidity
KALV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: KalVista Pharmaceuticals, Inc.'s revenue has declined by 21% over the 5-year period, indicating business contraction. The most recent EPS of $-3.44 indicates the company is currently unprofitable.
KALV Revenue Growth, EPS Growth & YoY Performance
KALV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.4M | -$23.5M | $-0.43 |
| Q3 2025 | $13.7M | -$25.3M | $-0.84 |
| Q3 2021 | $1.6M | -$5.9M | N/A |
| Q2 2021 | $3.9M | -$5.9M | N/A |
| Q1 2021 | $3.4M | -$7.3M | N/A |
| Q3 2020 | $1.6M | -$3.3M | N/A |
| Q2 2020 | $3.9M | -$3.3M | N/A |
| Q1 2020 | $3.4M | -$5.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KalVista Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
KALV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for KalVista Pharmaceuticals, Inc. (CIK: 0001348911)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 26, 2026 | 4 | xslF345X06/form4-05262026_110559.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_110530.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_110553.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_110523.xml | View → |
| May 26, 2026 | 4 | xslF345X06/form4-05262026_110551.xml | View → |
❓ Frequently Asked Questions about KALV
What is the AI rating for KALV?
KalVista Pharmaceuticals, Inc. (KALV) has a Combined AI Grade of B from Claude (B) and ChatGPT (B) with 54% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KALV's key strengths?
Claude: Exceptional revenue growth of 294% year-over-year demonstrates strong market traction. Fortress balance sheet with $243.5M cash (71% of total assets) and low debt burden (0.31x debt-to-equity). ChatGPT: Robust cash position and high current/quick ratios. Low leverage and limited long-term debt.
What are the risks of investing in KALV?
Claude: Severe cash burn of $127M operating cash flow and -$128.8M free cash flow with only $13.7M revenue limits runway without major inflection. Critically undercapitalized with only $17M stockholders equity against $339.9M liabilities creates vulnerability to adverse events. ChatGPT: Severe operating and net losses driving high cash burn. Thin shareholders’ equity versus sizable liabilities, elevating dilution risk.
What is KALV's revenue and growth?
KalVista Pharmaceuticals, Inc. reported revenue of $13.7M.
Does KALV pay dividends?
KalVista Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find KALV SEC filings?
Official SEC filings for KalVista Pharmaceuticals, Inc. (CIK: 0001348911) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KALV's EPS?
KalVista Pharmaceuticals, Inc. has a diluted EPS of $-2.97.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is KALV's fundamental grade?
Based on our AI fundamental analysis in May 2026, KalVista Pharmaceuticals, Inc. has a B grade with 54% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is KALV stock overvalued or undervalued?
Valuation metrics for KALV: ROE of -934.8% (sector avg: 15%), net margin of -1,160.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is KALV's AI grade for 2026?
Our dual AI analysis gives KalVista Pharmaceuticals, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KALV's free cash flow?
KalVista Pharmaceuticals, Inc.'s operating cash flow is $-127.0M, with capital expenditures of $1.9M. FCF margin is -940.5%.
How does KALV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,160.0% (avg: 12%), ROE -934.8% (avg: 15%), current ratio 7.22 (avg: 2).